Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Elizabeth L. Hougen sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $53.02, for a total transaction of $318,120.00. Following the completion of the sale, the senior vice president now owns 16,392 shares of the company’s stock, valued at $869,103.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded up $1.44 during midday trading on Friday, hitting $56.93. 1,149,432 shares of the stock were exchanged, compared to its average volume of 1,468,307. Ionis Pharmaceuticals, Inc. has a twelve month low of $37.26 and a twelve month high of $65.51. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. The firm has a market capitalization of $7,080.00, a PE ratio of 352.87 and a beta of 2.89.

Several hedge funds and other institutional investors have recently bought and sold shares of IONS. Vanguard Group Inc. lifted its position in shares of Ionis Pharmaceuticals by 4.4% during the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Ionis Pharmaceuticals by 33.0% during the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after purchasing an additional 284,266 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Ionis Pharmaceuticals by 40.2% during the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after purchasing an additional 281,733 shares in the last quarter. BlackRock Inc. lifted its position in shares of Ionis Pharmaceuticals by 4.0% during the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after purchasing an additional 264,179 shares in the last quarter. Finally, Smith Asset Management Group LP acquired a new position in shares of Ionis Pharmaceuticals during the second quarter worth $11,394,000. 91.58% of the stock is currently owned by institutional investors and hedge funds.

IONS has been the subject of a number of recent analyst reports. Stifel Nicolaus restated a “hold” rating and issued a $50.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price objective for the company in a research note on Friday, October 27th. Morgan Stanley boosted their price objective on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 8th. BMO Capital Markets boosted their price objective on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Finally, Barclays began coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They set an “equal weight” rating and a $55.00 price objective for the company. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $50.31.

WARNING: “Elizabeth L. Hougen Sells 6,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/12/01/elizabeth-l-hougen-sells-6000-shares-of-ionis-pharmaceuticals-inc-ions-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.